Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Bezmialem Vakıf University Istanbul, Turkey; Department of Medical Microbiology, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa, Istanbul 34098, Turkey.
Department of Infectious Diseases and Clinical Microbiology, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa, Istanbul 34098, Turkey.
Vaccine. 2022 Jan 3;40(1):52-58. doi: 10.1016/j.vaccine.2021.11.051. Epub 2021 Nov 22.
Healthcare workers (HCWs) were among the first groups to be vaccinated in Turkey. The data to be obtained by the vaccination of HCWs would guide wide spread vaccination programs.
The study included 330 HCWs working at Istanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty Hospital and vaccinated with inactive CoronaVac (Sinovac Life Sciences, China) SARS-CoV-2 vaccine in two doses (28 days apart). Anti-Spike /RBD IgG levels were measured 14 days after the first dose and 28 days after the second dose. Chemiluminescent microparticle immunoassay (CMIA) (ARCHITECT IgG II Quant test, Abbott, USA), which is 100% compatible with plaque reduction neutralization test (PRNT), was used.
Of the participants, 211 (63.9%) were female, 119 (36.1%) were male, and mean age was 39.6 ± 7.7 years. In those without prior COVID-19 history; (n = 255) antibody positivity was detected as 48.2% (95% CI: 42.1-54.3) 14 days after the first dose of vaccine, and 99.2% (95% CI: 98.1-100) at day 28 after the second dose. Antibody titers were significantly lower in patients with hypertension (p = 0.011). In those with prior history of COVID-19 (n = 75); both the antibody positivity rates after the first vaccine (48.2% vs 100%, p = 0.000) and the anti-spike/RBD antibody levels after the second vaccine (with a ≥ 1050 AU/mL titer equivalent to PRNT 1/80 dilution) was significant than infection-naive group (25.9% vs. 54.7%, p = 0.000). Antibody positivity after two doses of vaccination for all study group was 99.4% (95% CI: 98.6-100).
Two doses CoronaVac produce effective humoral immunity in HCWs. Antibody response is significantly higher in those with prior history of COVID-19 than infection-naive group. Given no significant benefit of the second dose, a single shot of vaccination may be sufficient for those with prior history of COVID-19. Monitoring humoral and cellular immune responses, considering new variants, is required to validate this approach.
医护人员（HCWs）是最早接种疫苗的人群之一。通过对 HCWs 进行疫苗接种获得的数据将指导广泛的疫苗接种计划。
本研究纳入了在伊斯坦布尔大学 - 切拉帕萨、切拉帕萨医学系医院工作并接种了两剂灭活科兴（中国科兴生物）SARS-CoV-2 疫苗（间隔 28 天）的 330 名 HCWs。在第一剂后 14 天和第二剂后 28 天测量抗刺突/RBD IgG 水平。采用化学发光微粒子免疫分析法（CMIA）（ARCHITECT IgG II Quant 检测，雅培，美国），该方法与蚀斑减少中和试验（PRNT）完全兼容。
在参与者中，211 名（63.9%）为女性，119 名（36.1%）为男性，平均年龄为 39.6±7.7 岁。在无既往 COVID-19 病史的人群中（n=255），疫苗接种后 14 天，抗体阳性率为 48.2%（95%CI：42.1-54.3），第二剂后 28 天为 99.2%（95%CI：98.1-100）。高血压患者的抗体滴度显著较低（p=0.011）。在有既往 COVID-19 病史的人群中（n=75），第一剂疫苗后抗体阳性率（48.2%比 100%，p=0.000）和第二剂疫苗后抗刺突/RBD 抗体水平（抗体滴度≥1050 AU/mL 与 PRNT 1/80 稀释相当）均显著高于无感染史组（25.9%比 54.7%，p=0.000）。所有研究组接种两剂疫苗后的抗体阳性率为 99.4%（95%CI：98.6-100）。
两剂科兴疫苗可在 HCWs 中产生有效的体液免疫。与无感染史组相比，有既往 COVID-19 病史的患者抗体反应显著更高。由于第二剂疫苗没有显著获益，对于有既往 COVID-19 病史的患者，单次接种疫苗可能就足够了。需要监测体液和细胞免疫反应，并考虑新的变异株，以验证这一方法。
